was a big mover last session, as the company saw its shares rise by over 8% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the stock, as it is now trading above the volatile price range of $20.32 to $21.71 in the past one-month time frame.
This generic drug company has seen a mixed track record when it comes to estimate revision. One estimate each has moved up and down in the last one month. The Zacks Consensus Estimate, however, has remained unchanged over the same time period. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Akorn currently has a Zacks Rank #3 (Hold) while its Earnings ESP
Some better performing stocks in the same industry include Impax Laboratories Inc.
(IPXL - Analyst Report
) and Supernus Pharmaceuticals, Inc.
(SUPN - Snapshot Report
), holding a Zacks Rank #1 (Strong Buy) and a Zacks Rank #2 (Buy), respectively. Another stock in the broader healthcare sector worth considering is Cynosure, Inc.
(CYNO - Snapshot Report
) with a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days
. Click to get this free report >>